News Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:11 13/03/2026 GMT			5-day change	1st Jan Change
320.70 ^CHF	+0.79%		-6.01%	-2.29%

03-12	ROCHE HOLDINGS AG : Deutsche Bank reaffirms its Neutral rating	ZD
03-12	ROCHE HOLDINGS AG : Receives a Buy rating from Barclays	ZD

All News

03-12	ROCHE HOLDINGS AG : Deutsche Bank reaffirms its Neutral rating	ZD
03-12	ROCHE HOLDINGS AG : Receives a Buy rating from Barclays	ZD
03-12	ROCHE HOLDINGS AG : JP Morgan is Neutral	ZD
03-12	Swiss stocks - Factors to watch on March 12	RE
03-11	For final dividend	FA
03-11	Regenxbio's Duchenne gene therapy shows improved muscle function in trial	RE
03-11	AlphaValue/Baader Europe Upgrades Roche to Add Rating, Trims PT	MT
03-11	ROCHE HOLDINGS AG : Gets a Neutral rating from Berenberg	ZD
03-11	Berenberg Keeps Roche at Hold Amid 'Mixed Fortunes' for Immunology, Oncology Portfolios	MT
03-10	Roche Holding Ag Approves Dividend Increase	CI
03-10	MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer	CI
03-10	Roche Holding Ag Elects Lubomira Rochet to the Board of Directors	CI
03-10	ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating	ZD
03-10	Glooko Integrates Roche Accu-Chek Smartguide CGM into Platform in Key European Markets	CI
03-10	Swiss stocks - Factors to watch on March 10	RE
03-09	Roche Provides Update On Phase III Persevera Study In Er-Positive Advanced Breast Cancer	CI
03-09	Xencor Inc Announces Termination Of Collaboration And License Agreement With Genentech Inc And F Hoffmann-La Roche Ltd	CI
03-09	Roche Holding AG - Special Call
03-09	European shares close lower as oil spike intensifies inflation worries	RE
03-09	Swiss Market Index Starts Week in Red; Roche Sheds	MT
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE
03-09	Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update	DJ
03-09	Correction to Roche Shares Article	DJ
03-09	Investors Confront Stagflation Risk
03-09	Roche Shares Slide as Breast Cancer Drug Combination Misses Statistical Significance in Late-stage Trial	MT